TEVA: תחזית צמיחת רווחים לשנה הבאה Teva Pharmaceuticals

לוגו גרפי של Teva Pharmaceutical Industries (TEVA)

The projected net profit growth for Teva Pharmaceutical Industries (TEVA) reflects current market expectations, where the metric value stands at 51.70. This positive momentum is based on Teva Pharmaceutical Industries (TEVA) leadership in the biosimilars segment and CNS developments. The development vector relies on a balance between affordable therapy and the creation of unique drugs, although severe pricing pressure in the generics niche limits its pricing power.

Teva Pharma (TEVA): קצב צמיחה חזוי של רווח למניה לשנה הבאה מ-04.07.2022 עד 18.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Teva Pharmaceuticals (TEVA)

ניתוח פונדמנטלי של החברה:Teva Pharmaceutical Industries
פריט של המותג Teva

The projected earnings growth for the coming year allows for an assessment of whether Teva Pharmaceutical Industries (TEVA) market value aligns with its future potential. By analyzing the trend of market expectations for EPS growth, an investor can determine the percentage change in expected earnings per share relative to the current period. This metric is calculated as the ratio of the projected EPS to the actual figure from the previous year. For Teva Pharmaceutical Industries (TEVA), this indicator confirms the defensive qualities of the business, as demand for generics remains stable regardless of economic cycles.